Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 30, 2012

Life and Sino Sign Distribution and Development Pact

  • Life Technologies and China’s Sino Biological signed a worldwide product distribution and development agreement, through which Life will distribute its new partner’s portfolio of recombinant proteins, antibodies, and Elisa kits worldwide, including over 2,000 recombinant proteins and 3,000 antibody products. The two firms will also work together to develop new proteomics products for applications in areas including flow cytometry and imaging.

    “Sino Biological’s mission is to develop the best quality biological tools to assist scientists,” comments Liangzhi Xi, Ph.D., president and CEO at Sino. “Combining our state-of-the-art disruptive technologies in recombinant protein production and antibody development with Life Technologies’ innovative product development and worldwide marketing will allow us to bring powerful research tools to scientists solving critical puzzles in life science research and drug discovery.”

    Established in 2007, Sino is a major manufacturer and supplier of cDNA, recombinant protein, and antibody products to the biomedical and pharmaceutical research industries. The firm says it has the in-house capability and capacity to produce over 1,000 new recombinant proteins per year in bulk, and has commercialized over 10,000 products. 

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »